Stock Taper
SCREENER COMPARE ANY 2 STOCKS
DWTX
DOGWOOD THERAPEUTICS, INC.
NASDAQ
$2.65
▲ UP 14.22% (0.33)

KEY STATISTICS

Market Cap$89.12 M
52w High$9.50
52w Low$1.28
Dividend Yield—
Frequency—
P/E-0.25
Volume133.66K
Shares Out.33.63M

COMPANY

LEADERSHIP

Gregory Duncan
CHIEF EXECUTIVE
Gregory Duncan

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 17, 2020
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
8

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU

PRICE

$2.65 ▲ UP 14.22% (+$0.33)
$2.40$2.50$2.60$2.709:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.65

About Dogwood Therapeutics, Inc.

https://www.dwtx.com ↗

Dogwood Therapeutics, Inc., founded in 2012 and based in Alpharetta, Georgia, develops novel antiviral therapies, including IMC-1 for fibromyalgia and IMC-2 for long COVID symptoms.

INDUSTRY

Biotechnology

A PRODUCT DOGWOOD THERAPEUTICS, INC. IS KNOWN FOR

Halneuron®
Halneuron®

Halneuron® is a Phase 2b non-opioid NaV 1.7 inhibitor, FDA fast-track designated, developed by Dogwood Therapeutics to treat pain, especially chemotherapy-induced neuropathic pain.

COMPETITORS

COMPETITOR
LLY COMPARE
PRAX COMPARE
VRTX COMPARE
XENE COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
2
LISTED HERE
2
RANKED BY POSITION SIZE
VXF
0.00% · 132.2K
IWC
0.00% · 27.0K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR
Whitley Richard James
Purchase · 16.8K shares
2026-06-16
★
DIRECTOR
Keefer David R
Purchase · 16.8K shares
2026-06-16
★
DIRECTOR
De La Rosa Abel
Purchase · 16.8K shares
2026-06-16
★
DIRECTOR
Thomas John C
Purchase · 16.8K shares
2026-06-16

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
EDSA$4.62COMPARE
CLRB$2.53COMPARE
COCP$1.10COMPARE
TRAW$0.59COMPARE
BOLT$3.81COMPARE
IMNN$1.60COMPARE
BRTX$0.20COMPARE
EVGN$0.55COMPARE